Cytomegalovirus-specific cell-mediated immunity for prediction of post-prophylaxis CMV disease in a phase 3 trial of letermovir vs valganciclovir prophylaxis in donor CMV-seropositive recipient CMV-seronegative kidney transplant recipients

Journal:

Clinical Infectious Diseases

Published:

2025-12-01

DOI:

10.1093/cid/ciaf632

Affiliations:

9

Authors:

9

Go to article

Institutions	Authors	Share
Merck & Co, United States of America (USA)	3.000000	0.33
University of California, San Francisco (UCSF), United States of America (USA)	1.000000	0.11
University Health Network (UHN), U of T, Canada	1.000000	0.11
Australian Red Cross Lifeblood, Australia	1.000000	0.11
Columbia University Irving Medical Center (CUIMC), CU, United States of America (USA)	1.000000	0.11
Hospital del Mar Medical Research Institute (IMIM), Spain	0.500000	0.06
Pompeu Fabra University (UPF), Spain	0.500000	0.06
Toulouse Institute For Infectious and Inflammatory Diseases, France	0.500000	0.06
Toulouse University Hospital (CHU-Toulouse), France	0.500000	0.06

Interested in Immunology?